June 7, 2022
CellCept® (mycophenolate mofetil) has received an expanded indication for use in recipients of allogenic heart, kidney, or liver transplants who are at least three months old. It is used in combination with other immunosuppressants to prevent organ rejection.
- The updated indication allows for CellCept’s use in pediatric recipients of allogenic heart and liver transplants. The drug, which first received FDA approval in 1995, was previously indicated for these uses in adults only.
- CellCept is available in oral form as tablets, capsules, and an oral suspension. It is also available as an intravenous (IV) infusion that can be used up to 14 days for patients unable to take one of the oral formulations, though patients should be switched to oral dosing as soon as possible. Recommended dosing is based factors that include the patient’s age and body surface area, the type of transplant received, and the dosage form being used.